Mathurin-profile

     My research focuses on vaccine development and therapeutic strategies to combat emerging viral diseases. Currently, my primary goal is to develop a vaccine against dengue fever, the most prevalent arboviral disease, which still lacks a specific treatment. The safety and efficacy of the licensed dengue vaccines are still debated due to concerns about an increased risk of vaccine-breakthrough infections. Therefore, I am committed to developing a safe and effective dengue vaccine that offers balanced and long-lasting protection against all four DENV serotypes without the risk of enhanced disease.

     Additionally, my research extends to the development of a nasal COVID-19 vaccine that provides effective and broad protection against a spectrum of SARS-CoV-2 variants.

1.Jearanaiwitayakul T, Warit S, Lekjinda K, Seesen M, Limthongkul J, Midoeng P, Sunintaboon P, Ubol S. The Adjuvant Activity of BCG Cell Wall Cytoskeleton on a Dengue Virus-2 Subunit Vaccine. Vaccines, 2023;11(8).

2.Seesen M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, Sunintaboon P, Ubol S. a Bivalent Form of Nanoparticle-Based Dengue Vaccine Stimulated Responses that Potently Eliminate Both DENV-2 Particles and DENV-2-Infected Cells. Vaccine, 2023;41(9).

3.Seesen M, Jearanaiwitayakul T, Limthongkul J, Sunintaboon P, Ubol S. Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity. The Journal of general virology. 2022;103(7).

4.Jearanaiwitayakul T, Seesen M, Chawengkirttikul R, Limthongkul J, Apichirapokey S, Sapsutthipas S, Phumiamorn S. Sunintaboon P, Ubol S. Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2. Vaccines. 2021;9(7):768.